The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX-015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting
Open accessAbstract
ONYX-015 is an oncolytic virus untested as a treatment for malignant glioma. The NABTT CNS Consortium conducted a dose-escalation trial of intracerebral injections of ONYX-015. Cohorts of six patients at each dose level received doses of vector from 10(7) plaque-forming units (pfu) to 10(10) pfu into a total of 10 sites within the resected glioma cavity. Adverse events were identified on physical exams and testing of hematologic, renal, and liver functions. Efficacy data were obtained from serial MRI scans. None of the 24 patients experienced serious adverse events related to ONYX-015. The maximum tolerated dose was not reached at 10(10) pfu. The median time to progression after treatment with ONYX-015 was 46 days (range 13 to 452 + days). The median survival time was 6.2 months (range 1.3 to 28.0 + months). One patient has not progressed and 1 patient showed regression of interval-increased enhancement. With more than 19 months of follow-up, 1/6 recipients at a dose of 10(9) and 2/6 at a dose of 10(10) pfu remain alive. In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 10(10) pfu.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
The WHO classification of tumors of the nervous system
Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.215 · Cited by 1,547
Self-citationKhuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
Self-citationRampling, R., Cruickshank, G., Papanastassiou, V, Nicoll, J., Hadley, D., Brennan, D., Petty, R., MacLean, A., Harland, J., McKie, E., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 598
Hecht, J. R., Bedford, R. A., Abbruzzese, J. L., Lahoti, S., Reid, T. R., Soetikno, R. M., Kirn, D. H., & Freeman, S. M. (2003) · Clinical Cancer Research · Cited by 552
Self-citationKirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Self-citationNemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., McCarty, T., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 471
Ganly, I., Kirn, D. H., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C. C., et al. (2000) · PubMed · Cited by 432
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Self-citationPapanastassiou, V, Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R., & Brown, M. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301664 · Cited by 328
Dewey, R. A., Morrissey, G., Cowsill, C. M., Stone, D., Bolognani, F., Dodd, N. J. F., Southgate, T. D., Klatzmann, D., Lassmann, H., Castro, M. G., et al. (1999) · Nature Medicine · doi:10.1038/15207 · Cited by 311
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C. C., Uprichard, M. J., Hatfield, M. J., et al. (2002) · PubMed · Cited by 309
Antonio Chiocca, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc948 · Cited by 306
Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301398 · Cited by 299
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Adenovirus gene transfer causes inflammation in the brain
Byrnes, A. P., Rusby, J. E., Wood, M. J. A., & Charlton, H. M. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00068-t · Cited by 276
Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S.-H., Woo, S. L. C., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0030 · Cited by 262
Vasey, P. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1562 · Cited by 245
Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J., & Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301512 · Cited by 243
Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives
Hirschfeld, S., Ho, P. T. C., Smith, M., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.138 · Cited by 229
Current and future strategies for the treatment of malignant brain tumors
Castro, M. G., Cowen, R., Williamson, I. K., David, A., Jimenez-Dalmaroni, M. J., Yuan, X., Bigliari, A., Williams, J. C., Hu, J., & Lowenstein, P. R. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00014-7 · Cited by 188
Boviatsis, E., Chase, M., Wei, M., Tamiya, T., Hurford, R. K., Kowall, N. W., Tepper, R. I., Breakefield, X. O., & Chiocca, E. A. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.2-183 · Cited by 156
Self-citationGermano, I. M., Fable, J., Gultekin, S. H., & Silvers, A. (2003) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000003657.95085.56 · Cited by 148
Makower, D., Rozenblit, A. M., Kaufman, H. L., Edelman, M. C., Lane, M. E., Zwiebel, J. A., Haynes, H., & Wadler, S. (2003) · PubMed · Cited by 148
Self-citationPhase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
Hamid, O., Varterasian, M. L., Wadler, S., Hecht, J. R., Benson, A. B., Galanis, E., Uprichard, M. J., Omer, C. A., Bycott, P. W., Hackman, R. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.114 · Cited by 146
LaMont, J., Nemunaitis, J. J., Kuhn, J. A., Landers, S. A., & McCarty, T. M. (2000) · Annals of Surgical Oncology · doi:10.1007/bf02725338 · Cited by 123
Ganly, I., Eckhardt, S. G., Rodriguez, G. I., et al. (2000) · Clinical Cancer Research · Cited by 123
Smitt, P. A. E. S., Driesse, M. J., Wolbers, J. G., Kros, M., & Avezaat, C. J. J. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00100-x · Cited by 110
Nemunaitis, J. J., Cunningham, C., Tong, A. W., Post, L. E., Netto, G. J., Paulson, A. S., Rich, D., Blackburn, A., Sands, B. E., Gibson, B., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700585 · Cited by 90
Self-citationEdwards, S. J., Dix, B. R., Myers, C. J., Dobson-Le, D., Huschtscha, L. I., Hibma, M. H., Royds, J. A., & Braithwaite, A. W. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12483-12490.2002 · Cited by 73
Temozolomide in malignant gliomas.
Yung, W. K. A. (2000) · PubMed · Cited by 63
Bhat, N. R., & Fan, F. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02953-0 · Cited by 54
Liver-directed viral therapy for cancer
Warren, R. S., & Kirn, D. H. (2002) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(02)00043-1 · Cited by 22
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Current state of immunotherapy for glioblastoma
Lim, M., Xia, Y., Bettegowda, C., & Weller, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0003-5 · Cited by 1,365
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Immunotherapy for glioma: Current management and future application
Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.002 · Cited by 746
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Self-citation
Metadata
- Authors
- Chiocca, E. A., Abbed, K. M., Tatter, S., Louis, D. N., Hochberg, F. H., Barker, F., Kracher, J., Grossman, S. A., Fisher, J. D., Carson, K., Rosenblum, M., Mikkelsen, T., Olson, J., Markert, J., Rosenfeld, S., Nabors, L. B., Brem, S., Phuphanich, S., Freeman, S., Kaplan, R., & Zwiebel, J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 10
- Issue
- 5
- Pages
- 958-966
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1983766005
- Cited by
- 436
- References
- 34
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.